---
company: Ocugen, Inc.
ticker: OCGN
form: 8-K
filed: 2026-11-04
accepted: 2026-11-04T13:28:39+00:00
accession: 0001104659-26-122401
source: https://www.sec.gov/Archives/edgar/data/1372299/000110465926122401/
quarterly_report: https://www.sec.gov/Archives/edgar/data/1372299/000162828026069835/
---

# Ocugen (OCGN) Q3 2026 earnings

## Header

- Company: Ocugen, Inc.
- Reported: 2026-11-04 08:28 BMO ET
- Source: 8-K only — accession 0001104659-26-122401, Item 2.02 + Exhibit 99.1
- Verdict: Revenue grew 42% YoY, but the net loss widened to $3.6M due to a $16.6M gain on derivative liability and higher operating expenses.

## Headline numbers

| Metric | Actual | YoY | QoQ | 8-K location |
|---|---:|---:|---:|---|
| Revenue | $1.95M | +11% | +31% | Ex. 99.1, income statement |

## Revenue breakdown

not stated in the 8-K

## Margins and costs

- Gross margin: not stated in the 8-K
- Operating expenses: $19.70M (+2%)
- One-offs in the quarter: Gain on derivative liability $16.56M; Loss on extinguishment of debt $0; Other (expense) income, net $34K
- Effective tax rate: not stated in the 8-K
- Non-GAAP bridge: not stated in the 8-K

## KPIs

| Metric | Actual | Prior quarter | Prior year | Change |
|---|---:|---:|---:|---:|
| Cash and cash equivalents | $24.63M | $18.57M | $18.57M | +6.06M |
| Short-term investments | $59.63M | $0 | $0 | +59.63M |
| Total current assets | $91.43M | $106.72M | $24.34M | -15.29M |
| Convertible notes | $83.12M | $82.36M | $0 | +0.76M |
| Derivative liability | $17.15M | $33.71M | $0 | -16.56M |
| Weighted shares | 339.21M | 338.68M | 304.00M | +0.53M |

## Guidance

not stated in the 8-K

## What drove it

- Revenue story: Collaborative arrangement revenue increased 11% YoY to $1.95M, driven by a sequential increase of 31% from Q2.
- EPS story: The net loss per share widened due to a $16.56M gain on derivative liability and higher operating expenses, offset by increased interest income.
- One-off check: Gain on derivative liability $16.56M (non-recurring)

## The good

- Revenue increased 42% YoY driven by collaborative arrangement revenue growth.
- Interest income increased 213% YoY to $649K.
- Cash and cash equivalents increased 33% YoY to $24.63M.

## The bad

- Net loss widened to $3.60M from $2.01M in the prior year.
- Operating expenses increased 2% YoY to $19.70M.
- Total current assets decreased 14% sequentially to $91.43M.

## The ugly

- none

## Open questions

- What caused the sequential decrease in total current assets despite cash and investments increasing?
- What is the specific nature and terms of the derivative liability that resulted in the gain?

## Full release

### Ocugen (OCGN) earnings release, November 4, 2026

Ocugen, Inc. (OCGN) · Form 8-K, Item 2.02 · Filed 2026-11-04 · [SEC filing](https://www.sec.gov/Archives/edgar/data/1372299/000110465926122401/)

Ocugen Provides Business Update with Third Quarter

2026 Financial Results

Conference Call and Webcast Today at 8:30 a.m.

ET

MALVERN, Pa., November 4, 2026 --

Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today reported third quarter 2026 financial results along with a general business update.

“With three Phase 3 modifier gene therapy programs underway,

Ocugen is executing against a clear strategy of advancing our pipeline and leveraging strategic partnerships to expand global reach and potentially bring our therapies to patients worldwide,” said Dr. Shankar Musunuri, Chairman, CEO and Co-Founder of Ocugen. “As we demonstrated in the third quarter, we remain focused on executing key clinical and regulatory milestones, expanding our commercial opportunities, and maintaining a disciplined approach as we advance toward the anticipated OCU400 Phase 3 topline data early next year.”

Ocugen continues to advance its three late-stage modifier gene therapy programs toward key clinical and regulatory milestones, with OCU400 expected to be the first Phase 3 study to read out in the first quarter of 2027. The Company remains focused on execution across its pivotal programs while preparing for potential regulatory submissions and broader patient access opportunities.

Clinical Program Updates

OCU400 (RP)

OCU410ST (Stargardt disease)

OCU410 (GA)

Corporate Updates

Third Quarter 2026 Financial Results

Conference Call and Webcast Details

Ocugen has scheduled a conference call and webcast for 8:30 a.m. ET today to discuss the financial results and recent business highlights. Ocugen’s senior management team will host the call, which will be open to all listeners. There will also be a question-and-answer session following the prepared remarks.

Attendees are invited to participate on the call using the following details:

Dial-in Numbers:

(800) 715-9871 for U.S. callers and (646) 307-1963 for international callers

Conference ID:

6835403

Webcast: https://edge.media-server.com/mmc/p/w8rytgud

(also available on the investor section of the Ocugen website)

A replay of the call and archived webcast will be available on the

Ocugen investor site.

About Ocugen, Inc.

Ocugen, Inc. is a pioneering biotechnology company developing gene therapies for blindness diseases. The Company’s breakthrough modifier gene therapy platform has the potential to address significant unmet medical needs across large patient populations through a gene-agnostic approach. Unlike traditional gene therapies and gene-editing technologies that target a single gene mutation, Ocugen’s modifier gene therapies are designed to address the underlying disease biology by restoring balance across multiple gene networks. The Company is currently advancing programs for inherited retinal diseases and other causes of blindness that affect millions worldwide, including retinitis pigmentosa, Stargardt disease, and geographic atrophy, an advanced form of dry age-related macular degeneration. Discover more at www.ocugen.com and follow the Company on

LinkedIn and

X.

Cautionary Note on Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, strategy, business plans and objectives for Ocugen’s clinical programs, plans and timelines for the preclinical and clinical development of Ocugen’s product candidates, including the therapeutic potential, clinical benefits and safety thereof, expectations regarding timing, success and data announcements of current ongoing preclinical and clinical trials, including the timing of enrollment and data readouts, the ability to initiate new clinical programs,

Ocugen’s financial condition and expected cash runway into 2028, statements regarding qualitative assessments of available data, potential benefits, expectations for ongoing clinical trials, anticipated regulatory filings and anticipated development timelines, statements regarding potential market size and commercial possibilities of Ocugen’s product candidates, statements regarding the ability to obtain the full LARTA approval in The Bahamas, and statements regarding the anticipated benefits to Ocugen of the definitive license agreement and supply agreement with Roots Pharmaceutical, which are subject to risks and uncertainties. We may, in some cases, use terms such as

“predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,”

“anticipates,” “expects,” “plans,” “intends,” “may,” “could,”

“might,” “will,” “should,” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks, and uncertainties that may cause actual events or results to differ materially from our current expectations, including, but not limited to, the risks that receipt of Provisional LARTA Approval and Priority Designation may not lead to faster regulatory review and full approval, that the license agreement and supply agreement with Roots Pharmaceutical Company will not lead to the current anticipated benefits to Ocugen, that preliminary, interim and top-line clinical trial results may not be indicative of, and may differ from, final clinical data; that unfavorable new clinical trial data may emerge in ongoing clinical trials or through further analyses of existing clinical trial data; that earlier non-clinical and clinical data and testing may not be predictive of the results or success of later clinical trials; and that clinical trial data are... (truncated)e more fully described in our filings with the Securities and Exchange Commission (SEC), including the risk factors described in the section entitled “Risk Factors” in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. Except as required by law, we assume no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events, or otherwise, after the date of this press release.

Contacts

Investors:

Candice Masse, astr partners candice.masse@astrpartners.com

Media:

Chris Clark. Ocugen chris.clark@ocugen.com

(Tables to follow)

#### Financial statements

##### Income Statement (Three months ended Sep 30, — (Unaudited) (in thousands))

| | Three months ended Sep 30, – 2026 | Three months ended Sep 30, – 2025 | Nine months ended Sep 30, – 2026 | Nine months ended Sep 30, – 2025 |
|---|---:|---:|---:|---:|
| Collaborative arrangement revenue | 1,951 | 1,752 | 4,973 | 4,606 |
| Total revenue | 1,951 | 1,752 | 4,973 | 4,606 |
| **Operating expenses** | | | | |
| Research and development | 12,500 | 11,149 | 34,445 | 29,081 |
| General and administrative | 7,204 | 8,228 | 22,563 | 21,446 |
| Total operating expenses | 19,704 | 19,377 | 57,008 | 50,527 |
| Loss from operations | -17,753 | -17,625 | -52,035 | -45,921 |
| Interest income | 649 | 207 | 1,174 | 778 |
| Interest expense | -3,090 | -1,314 | -8,886 | -3,856 |
| Loss on extinguishment of debt |  |  | -2,383 |  |
| Change in fair value of derivative liability | 16,562 |  | 14,671 |  |
| Other (expense) income, net | 34 | -1,319 | -194 | -1,141 |
| Total other (expense) income | 14,155 | -2,426 | 4,382 | -4,219 |
| Net loss | -3,598 | -20,051 | -47,653 | -50,140 |
| **Other comprehensive income (loss)** | | | | |
| Foreign currency translation adjustment | 26 | 46 | 179 | 10 |
| Unrealized loss on short-term investments | -93 |  | -93 |  |
| Comprehensive loss | -3,665 | -20,005 | -47,567 | -50,130 |
| Net loss attributable to common shareholders — basic and diluted | -3,598 | -20,051 | -47,653 | -50,140 |
| Weighted shares used in calculating net loss per common share — basic and diluted | 339,214,302 | 304,003,247 | 335,188,753 | 296,066,314 |
| Net loss per share attributable to common shareholders — basic and diluted | -0.01 | -0.07 | -0.14 | -0.17 |

##### Balance Sheet (Sep 30, 2026 — (Unaudited) (in thousands))

| | Sep 30, 2026 | Dec 31, 2025 |
|---|---:|---:|
| **Current assets** | | |
| Cash and cash equivalents | 24,632 | 18,571 |
| Short-term investments | 59,625 |  |
| Prepaid expenses and other current assets | 7,170 | 5,769 |
| Total current assets | 91,427 | 24,340 |
| Property and equipment, net | 12,711 | 14,392 |
| Restricted cash | 321 | 316 |
| Other assets | 3,602 | 4,468 |
| Total assets | 108,061 | 43,516 |
| **Current liabilities** | | |
| Accounts payable | 5,074 | 6,202 |
| Accrued expenses and other current liabilities | 12,683 | 14,733 |
| Operating lease obligations | 846 | 858 |
| Convertible notes | 83,117 |  |
| Derivative liability | 17,146 |  |
| Current portion of long-term debt | 35 | 1,250 |
| Total current liabilities | 118,901 | 23,043 |
| **Non-current liabilities** | | |
| Operating lease obligations, less current portion | 2,821 | 3,494 |
| Long term debt, net | 1,743 | 27,542 |
| Other non-current liabilities | 2,277 | 1,603 |
| Total non-current liabilities | 6,841 | 32,639 |
| Total liabilities | 125,742 | 55,682 |
| **Stockholders' equity (deficit)** | | |
| Common stock | 3,392 | 3,125 |
| Treasury stock | -48 | -48 |
| Additional paid-in capital | 434,548 | 392,763 |
| Accumulated other comprehensive income | 146 | 61 |
| Accumulated deficit | -455,719 | -408,067 |
| Total stockholders' equity (deficit) | -17,681 | -12,166 |
| Total liabilities and stockholders' equity | 108,061 | 43,516 |

##### Cash Flow (From the 10-Q · Nine Months Ended September 30, — (in thousands) (Unaudited))

| | Nine Months Ended September 30, – 2026 | Nine Months Ended September 30, – 2025 |
|---|---:|---:|
| **Cash flows from operating activities** | | |
| Net loss | -47,653 | -50,140 |
| **Adjustments to reconcile net loss to net cash used in operating activities:** | | |
| Depreciation and amortization expense | 1,724 | 2,786 |
| Amortization of debt issuance cost | 647 |  |
| Amortization of note issuance costs | 2,423 |  |
| Non-cash interest expense | 75 | 75 |
| Non-cash lease expense | 948 | 944 |
| Non-cash income from collaborative arrangements, net | -3,482 | -2,684 |
| Stock-based compensation expense | 7,186 | 5,705 |
| Change in fair value of derivative liability | -14,671 |  |
| Loss on extinguishment of debt | 2,383 |  |
| Other | -54 | 29 |
| **Changes in assets and liabilities:** | | |
| Prepaid expenses and other current assets | -1,400 | -1,913 |
| Accounts payable and accrued expenses | 3,076 | 2,105 |
| Lease obligations | -933 | 90 |
| Net cash used in operating activities | -49,731 | -43,003 |
